Literature DB >> 11882630

Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors.

Fatima Z Ammarguellat1, Philippe O Gannon, Farhad Amiri, Ernesto L Schiffrin.   

Abstract

In deoxycorticosterone acetate (DOCA)-salt hypertension, the endothelin-1 system is activated and plays a role in cardiac fibrosis. Remodeling of extracellular matrix (ECM) may lead to interstitial fibrosis, which may contribute to heart failure. Imbalance in synthesis and degradation of the ECM by matrix metalloproteinases (MMPs) as well as inflammation may play a role in matrix protein deposition and cardiac remodeling in hypertension. We measured expression of the extracellular matrix protein fibronectin, the activity of the gelatinases MMP-2 and MMP-9, the proinflammatory transcription factor NFkappaB, and the adhesion molecules, vascular cell adhesion molecule (VCAM)-1 and platelet-endothelial cell adhesion molecule (PECAM)-1 in hearts of DOCA-salt hypertensive (DS) rats treated or not with the endothelin ET(A) antagonist BMS 182874 (BMS). Unilaterally nephrectomized rats (UniNx) were compared with DS rats treated or not with BMS 40 mg/kg/d. Fibronectin deposition was detectable at the first week, and remained elevated thereafter. This increase was abrogated by administration of the ET(A) antagonist. Enzymatic activity of gelatinases was increased (P<0.01) in DS compared with control during the first and second week. BMS blocked the increase of MMP-2 and MMP-9 activity at week 1 (P<0.05); MMP activity remained lower than in DS at week 2. NF-kappaB binding activity in DS was higher (P<0.05) than it was in controls during the second week, and was reduced by BMS. The adhesion molecules VCAM-1 and PECAM-1, and the antiapoptotic molecule xIAP were upregulated in the left ventricle of the heart of DS rats and downregulated in the rats treated with the ET(A) antagonist. In conclusion, cardiac extracellular remodeling in rats with endothelin-dependent hypertension was associated with increased fibronectin, MMP activity, and upregulation of inflammatory mediators, all of which were reduced by ET(A) antagonism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882630     DOI: 10.1161/hy0202.103481

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  34 in total

Review 1.  Matrix metalloproteinases: pathways of induction by bioactive molecules.

Authors:  Toshihiro Tsuruda; Lisa C Costello-Boerrigter; John C Burnett
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

Review 2.  Fistulising Crohn's disease: MMPs gone awry.

Authors:  D Schuppan; T Freitag
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

3.  Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis.

Authors:  Jeffrey C Horowitz; Iyabode O Ajayi; Priya Kulasekaran; David S Rogers; Joshua B White; Sarah K Townsend; Eric S White; Richard S Nho; Peter D R Higgins; Steven K Huang; Thomas H Sisson
Journal:  Int J Biochem Cell Biol       Date:  2011-10-25       Impact factor: 5.085

4.  Reversal of cardiac dysfunction by selective ET-A receptor antagonism.

Authors:  Anthony Allan; Andrew Fenning; Scott Levick; Andrew Hoey; Lindsay Brown
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

Review 5.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

Review 6.  Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload.

Authors:  Gabriele G Schiattarella; Joseph A Hill
Journal:  Circulation       Date:  2015-04-21       Impact factor: 29.690

Review 7.  Role of endothelin-1 in hypertension.

Authors:  Marc Iglarz; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

8.  Role of proteases in the pathophysiology of cardiac disease.

Authors:  Raja B Singh; Sucheta P Dandekar; Vijayan Elimban; Suresh K Gupta; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

Review 9.  Aldosterone: a risk factor for vascular disease.

Authors:  Mario Fritsch Neves; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

10.  2,5-Dimethylcelecoxib prevents pressure-induced left ventricular remodeling through GSK-3 activation.

Authors:  Ai Fujita; Fumi Takahashi-Yanaga; Sachio Morimoto; Tatsuya Yoshihara; Masaki Arioka; Kazunobu Igawa; Katsuhiko Tomooka; Sumio Hoka; Toshiyuki Sasaguri
Journal:  Hypertens Res       Date:  2016-09-15       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.